In this large retrospective analysis of COPD patients, those on 3 inhaled drugs (steroid, long acting beta agonist and tiotropium) has worse baseline lung function, but 35% lower all cause mortality, compared to those on 2 drugs (steroid and long acting beta agonist). This adds good evidence of benefit for 3 inhaled versus 2 inhaled drugs in lowering COPD mortality, although it has not been proven in a randomized controlled trial (abstract)
Share This Post
Categories
Related Posts
While spring 2020 feels like a lifetime ago, COVID-19 is still with us. Unfortunately, this winter has brought more infections, hospitalizations, and death rates that eclipse what many saw last spring. But this time, while the headlines are back about hospitals running low on PPE, ICU bed shortages, and long lines for testing, we now […]
This article is part of a series in The Hospital Leader written by members of the Division of Hospital Medicine at Dell Medical School at The University of Texas in Austin, exploring lessons learned from the coronavirus pandemic and outlining an approach for creating COVID-19 Centers of Excellence. Evidence on emerging treatments for COVID-19 has […]
While all of us see patients who smoke in their 70s or 80s, due to their limited lifespan from COPD, DM, malignancy, etc., and their expressed wishes to continue tobacco, we keep our admonitions to a minimum. We accept our patient has become learned enough through life to make their own decisions and accept whatever […]
Leave A Comment